



DOTTIKON ES Increases Net Sales and Profit

Dottikon, Switzerland, November 30, 2006 – DOTTIKON EXCLUSIVE SYNTHESIS, specialized in the exclusive synthesis of fine chemicals using hazardous chemical reactions, closed its business half-year on September 30.

Net sales increased by 4.1% from CHF 58.9 million to CHF 61.3 million compared to the last-year period. At the same time, the company was able to record a relatively large increase in net income of 20.8% to CHF 6.3 million.

The trend of global pharmaceutical companies to further defer chemical process development for the commercial manufacture of pharmaceutical active ingredients into later clinical phases continued in the past half-year. This makes rapid process development for commercial manufacturing, while simultaneously producing first quantities of active ingredient, the key success factor in exclusive synthesis. In the last reporting period DOTTIKON ES responded to this development by once again expanding its R&D and production capacities to achieve and secure performance leadership in hazardous reactions. Furthermore, measures were initiated to further qualitatively and quantitatively expand production capacities in the near future.

At its annual strategy meeting, the Board of Directors decided to further focus on hazardous reactions due to the growing demand in this area. Related to this decision, plants of products at the end of their life-cycle will be impaired in the second half-year. As a result the operating profit for the full current business year will be reduced by a special write-off of approximately CHF 4 million.

DOTTIKON ES continues to implement its strategic positioning as specialist for hazardous reactions and dedication to performance leadership. The focus will be set on high flexibility, speed, reliability and safety. For the business year 2006/07 the company expects a slight increase in net sales and a further improvement in the product mix.

The Annual Report 2006/07, covering the period from April 1, 2006 to March 31, 2007, will be presented at the beginning of June 2007.



Key Figures DOTTIKON ES Group

CHF million	FY 2005/06	HY 2005/06	HY 2006/07
Net sales	133.7*	58.9	61.3
EBITDA	29.8	12.3	13.4
<i>EBITDA margin (in % of net sales)</i>	<i>22.3%</i>	<i>20.8%</i>	<i>21.9%</i>
EBIT	18.0	6.4	7.5
<i>EBIT margin (in % of net sales)</i>	<i>13.5%</i>	<i>10.9%</i>	<i>12.2%</i>
Net income	13.6	5.2	6.3
<i>Net income margin (in % of net sales)</i>	<i>10.2%</i>	<i>8.9%</i>	<i>10.3%</i>

* Reclassification foreign exchange gains and losses related to sales in foreign currencies

FY: Business year from April 1, 2005 to March 31, 2006

HY: Business half-year from April 1 to September 30

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), specializes on hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

For further information please contact

Rémy Scheidegger
Senior Assistant to CEO

DOTTIKON ES HOLDING AG
Tel +41 56 616 82 01
Fax +41 56 616 89 45
remy.scheidegger@dottikon.com